Live news related to AMOEBA stock (FR0011051598): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on AMOEBA mainly cover M&A activity, analyst notes et the dividend and payout policy. The stock trades at €0,26 on Euronext Paris, down 3,58% at the last update. This page lists the articles published on AMOEBA stock to track the share price, company announcements and any item likely to influence market perception.
Through a press release published on October 27, 2026, Amoéba announced the completion of its capital increase with maintenance of preferential subscr…
Through a press release published on October 19, 2026, Amoéba reiterated the terms of its capital increase with maintenance of preemptive subscription…
The Lyon-based greentech company is bringing its existing shareholders into a financing operation designed to support the commercial launch of biocont…
Amoéba (microbiological biocontrol company based in Chassieu) presented on September 24, 2026 its roadmap through 2030, on the occasion of the publica…
Amoéba announced on Tuesday that it has obtained market authorization (MA) in France for its biofungicide Axpera, granted by ANSES. This first permane…
Amoéba announced on Monday that it has obtained a 120-day emergency authorization in Italy for its biofungicide Axpera, aimed at combating basil downy…
Amoéba's stock increases by 3.42% to €0.91 in mid-morning trading, going against the grain of a CAC 40 that is down by 0.89% at 8128.87 points. The bi…
Amoéba and its partner Koppert have obtained two large-scale experimental authorizations in the Netherlands for the biofungicide AXPERA, lasting two y…
Amoéba announces the emergency market authorization for its biocontrol product AXPERA, valid for 120 days, to combat vine downy mildew in France. This…
Amoéba (FR0011051598 - ALMIB) announces that it has conducted a comprehensive field testing program in Brazil, in partnership with Koppert, to evaluat…
